221 related articles for article (PubMed ID: 28467792)
21. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
22. Protein Kinases Alter the Allosteric Modulation of the Serotonin Transporter In Vivo and In Vitro.
Mnie-Filali O; Lau T; Matthaeus F; Abrial E; Delcourte S; El Mansari M; Pershon A; Schloss P; Sánchez C; Haddjeri N
CNS Neurosci Ther; 2016 Aug; 22(8):691-9. PubMed ID: 27171685
[TBL] [Abstract][Full Text] [Related]
23. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
Chen F; Larsen MB; Sánchez C; Wiborg O
Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064
[TBL] [Abstract][Full Text] [Related]
24. Functional Modulation of Na
Nakatani Y; Amano T
Biol Pharm Bull; 2018; 41(9):1471-1474. PubMed ID: 30175781
[TBL] [Abstract][Full Text] [Related]
25. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
26. Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram.
Rossi DV; Burke TF; Hensler JG
Eur J Pharmacol; 2008 Mar; 583(1):103-7. PubMed ID: 18289523
[TBL] [Abstract][Full Text] [Related]
27. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Stahl SM; Gergel I; Li D
J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
[TBL] [Abstract][Full Text] [Related]
28. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
29. Escitalopram affects spexin expression in the rat hypothalamus, hippocampus and striatum.
Pałasz A; Suszka-Świtek A; Filipczyk Ł; Bogus K; Rojczyk E; Worthington J; Krzystanek M; Wiaderkiewicz R
Pharmacol Rep; 2016 Dec; 68(6):1326-1331. PubMed ID: 27710862
[TBL] [Abstract][Full Text] [Related]
30. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
31. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram.
Sánchez C
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):91-5. PubMed ID: 16918708
[TBL] [Abstract][Full Text] [Related]
32. The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.
Montezinho LP; Miller S; Plath N; Jensen NH; Karlsson JJ; Witten L; Mørk A
Psychopharmacology (Berl); 2010 Oct; 212(2):131-43. PubMed ID: 20676614
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.
Drueke B; Baetz J; Boecker M; Moeller O; Hiemke C; Gründer G; Gauggel S
Psychopharmacology (Berl); 2009 Dec; 207(2):213-23. PubMed ID: 19756527
[TBL] [Abstract][Full Text] [Related]
34. Escitalopram's inflammatory effect on the mammalian macrophages and its intracellular mechanism of action.
Önal HT; Yetkin D; Ayaz F
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jul; 125():110762. PubMed ID: 37031947
[TBL] [Abstract][Full Text] [Related]
35. Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.
Leonard B; Taylor D
J Psychopharmacol; 2010 Aug; 24(8):1143-52. PubMed ID: 20147575
[TBL] [Abstract][Full Text] [Related]
36. Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study.
Guiard BP; Mansari ME; Murphy DL; Blier P
Int J Neuropsychopharmacol; 2012 Apr; 15(3):349-61. PubMed ID: 21439106
[TBL] [Abstract][Full Text] [Related]
37. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Hirschfeld RM; Vornik LA
J Clin Psychiatry; 2004; 65 Suppl 4():46-52. PubMed ID: 15046541
[TBL] [Abstract][Full Text] [Related]
38. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis.
Kasper S; Spadone C; Verpillat P; Angst J
Int Clin Psychopharmacol; 2006 Mar; 21(2):105-10. PubMed ID: 16421462
[TBL] [Abstract][Full Text] [Related]
39. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain.
El Mansari M; Sánchez C; Chouvet G; Renaud B; Haddjeri N
Neuropsychopharmacology; 2005 Jul; 30(7):1269-77. PubMed ID: 15702136
[TBL] [Abstract][Full Text] [Related]
40. Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.
Nguyen HT; Guiard BP; Bacq A; David DJ; David I; Quesseveur G; Gautron S; Sanchez C; Gardier AM
Br J Pharmacol; 2013 Jan; 168(1):103-16. PubMed ID: 22233336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
